首页 > 最新文献

CHEST pulmonary最新文献

英文 中文
Rebuttal From Dr Kim et al 反驳用于肺结节风险分层的液体标记物,准备好了吗?尚未!(赞成 PRO)
Pub Date : 2024-09-01 DOI: 10.1016/j.chpulm.2024.100069
{"title":"Rebuttal From Dr Kim et al","authors":"","doi":"10.1016/j.chpulm.2024.100069","DOIUrl":"10.1016/j.chpulm.2024.100069","url":null,"abstract":"","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789224000357/pdfft?md5=559ef83bde3a7c5f851a39ffd03fa2c1&pid=1-s2.0-S2949789224000357-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141392961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rebuttal From Dr Nadig et al 用于肺结节风险分层的液体标记物,准备好了吗?还没反驳
Pub Date : 2024-09-01 DOI: 10.1016/j.chpulm.2024.100068
{"title":"Rebuttal From Dr Nadig et al","authors":"","doi":"10.1016/j.chpulm.2024.100068","DOIUrl":"10.1016/j.chpulm.2024.100068","url":null,"abstract":"","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789224000345/pdfft?md5=2bc971119d8bd1dbbca2e46885feec49&pid=1-s2.0-S2949789224000345-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141406179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dyspnea in a Patient With Metastatic Breast Cancer 一名转移性乳腺癌患者的呼吸困难
Pub Date : 2024-09-01 DOI: 10.1016/j.chpulm.2024.100074

Case Presentation

A 76-year-old female with a history of estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast cancer presented to the pulmonary clinic with severe exertional dyspnea. She had no known history of cardiopulmonary disease and was in her usual state of health until 3 months prior to her presentation when she was diagnosed with a breast cancer recurrence in an axillary lymph node with associated osseous metastases. Subsequently, she had developed rapidly progressive exercise intolerance, orthopnea, and lower extremity edema.

病例介绍 一位 76 岁的女性患者,曾患雌激素受体阳性/孕激素受体阳性/HER2 阴性乳腺癌,因严重的劳力性呼吸困难到肺科门诊就诊。她没有已知的心肺疾病史,平时健康状况良好,直到就诊前 3 个月,她被诊断为乳腺癌腋窝淋巴结复发并伴有骨转移。随后,她出现了快速进展的运动不耐受、呼吸困难和下肢水肿。
{"title":"Dyspnea in a Patient With Metastatic Breast Cancer","authors":"","doi":"10.1016/j.chpulm.2024.100074","DOIUrl":"10.1016/j.chpulm.2024.100074","url":null,"abstract":"<div><h3>Case Presentation</h3><p>A 76-year-old female with a history of estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast cancer presented to the pulmonary clinic with severe exertional dyspnea. She had no known history of cardiopulmonary disease and was in her usual state of health until 3 months prior to her presentation when she was diagnosed with a breast cancer recurrence in an axillary lymph node with associated osseous metastases. Subsequently, she had developed rapidly progressive exercise intolerance, orthopnea, and lower extremity edema.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789224000400/pdfft?md5=8d86ff6674243e6331b7d8532856a85f&pid=1-s2.0-S2949789224000400-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141394144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Male Sex With Worse Right Ventricular Function and Survival in Pulmonary Hypertension in the Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics Cohort 在 PVDOMICS 队列中,男性与肺动脉高压患者较差的右心室功能和存活率有关
Pub Date : 2024-09-01 DOI: 10.1016/j.chpulm.2024.100046

Background

Sex-based differences are important in the development and progression of pulmonary arterial hypertension. However, it is not established whether these differences are generalizable to all forms of pulmonary hypertension (PH).

Research Question

What are the sex-based differences in right ventricle (RV) function and transplant-free survival in patients with PH from the Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics (PVDOMICS) cohort?

Study Design and Methods

Patients with PH enrolled in the PVDOMICS cohort study underwent right heart catheterization, cardiac MRI, and echocardiography. A multivariable linear regression model was used to investigate the interactive effect between sex and pulmonary vascular resistance (PVR) on RV ejection fraction (RVEF). Effects of sex, RVEF, and PVR on transplant-free survival were assessed using a Cox proportional hazards model.

Results

Seven hundred fifty patients with PH (62.8% female) were enrolled, including 397 patients with groups 2 through 5 PH. Patients with group 1 PH were predominantly female (73.4%). Male patients showed multiple markers of worse RV function with significantly lower RVEF (adjusted difference, 5.5%; 95% CI, 3.2%-7.8%; P < .001) on cardiac MRI and lower RV fractional shortening (adjusted difference, 4.0%; 95% CI, 2.3%-5.8%; P < .001) and worse RV free-wall longitudinal strain (adjusted difference, 2.4%; 95% CI, 1.2%-3.6%; P < .001) on echocardiography. Significant interaction was noted between PVR and sex on RVEF, with the largest sex-based differences in RVEF noted at mild to moderate PVR elevation. Male sex was associated with decreased transplant-free survival (adjusted hazard ratio, 1.46; 95% CI, 1.07-1.98; P = .02), partially mediated by differences in RVEF (P = .003).

Interpretation

In patients with PH in the PVDOMICS study, female sex was more common, whereas male sex was associated with worse RV function and decreased transplant-free survival, most notably at mild to moderate elevation of PVR.

Trial Registry

ClinicalTrials.gov; No.: NCT02980887; URL: www.clinicaltrials.gov

研究背景性别差异在肺动脉高压的发生和发展过程中非常重要。研究设计和方法参加 PVDOMICS 队列研究的 PH 患者接受了右心导管检查、心脏核磁共振成像和超声心动图检查。采用多变量线性回归模型研究了性别和肺血管阻力(PVR)对RV射血分数(RVEF)的交互影响。采用 Cox 比例危险度模型评估了性别、RVEF 和 PVR 对无移植生存期的影响。结果共纳入了 75 名 PH 患者(62.8% 为女性),其中包括 397 名第 2 组至第 5 组 PH 患者。PH 第 1 组患者主要为女性(73.4%)。男性患者表现出多种 RV 功能较差的标记,心脏 MRI 上的 RVEF 明显较低(调整后差异为 5.5%;95% CI,3.2%-7.8%;P < .001),超声心动图上的 RV 分形缩短率较低(调整后差异为 4.0%;95% CI,2.3%-5.8%;P < .001),RV 游离壁纵向应变较差(调整后差异为 2.4%;95% CI,1.2%-3.6%;P < .001)。PVR和性别对RVEF有显著的交互作用,轻度至中度PVR升高时RVEF的性别差异最大。在PVDOMICS研究的PH患者中,女性更为常见,而男性则与RV功能较差和无移植生存率下降有关,尤其是在轻度至中度PVR升高时。试验注册中心ClinicalTrials.gov; No.
{"title":"Association of Male Sex With Worse Right Ventricular Function and Survival in Pulmonary Hypertension in the Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics Cohort","authors":"","doi":"10.1016/j.chpulm.2024.100046","DOIUrl":"10.1016/j.chpulm.2024.100046","url":null,"abstract":"<div><h3>Background</h3><p>Sex-based differences are important in the development and progression of pulmonary arterial hypertension. However, it is not established whether these differences are generalizable to all forms of pulmonary hypertension (PH).</p></div><div><h3>Research Question</h3><p>What are the sex-based differences in right ventricle (RV) function and transplant-free survival in patients with PH from the Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics (PVDOMICS) cohort?</p></div><div><h3>Study Design and Methods</h3><p>Patients with PH enrolled in the PVDOMICS cohort study underwent right heart catheterization, cardiac MRI, and echocardiography. A multivariable linear regression model was used to investigate the interactive effect between sex and pulmonary vascular resistance (PVR) on RV ejection fraction (RVEF). Effects of sex, RVEF, and PVR on transplant-free survival were assessed using a Cox proportional hazards model.</p></div><div><h3>Results</h3><p>Seven hundred fifty patients with PH (62.8% female) were enrolled, including 397 patients with groups 2 through 5 PH. Patients with group 1 PH were predominantly female (73.4%). Male patients showed multiple markers of worse RV function with significantly lower RVEF (adjusted difference, 5.5%; 95% CI, 3.2%-7.8%; <em>P &lt;</em> .001) on cardiac MRI and lower RV fractional shortening (adjusted difference, 4.0%; 95% CI, 2.3%-5.8%; <em>P &lt;</em> .001) and worse RV free-wall longitudinal strain (adjusted difference, 2.4%; 95% CI, 1.2%-3.6%; <em>P &lt;</em> .001) on echocardiography. Significant interaction was noted between PVR and sex on RVEF, with the largest sex-based differences in RVEF noted at mild to moderate PVR elevation. Male sex was associated with decreased transplant-free survival (adjusted hazard ratio, 1.46; 95% CI, 1.07-1.98; <em>P =</em> .02), partially mediated by differences in RVEF (<em>P =</em> .003).</p></div><div><h3>Interpretation</h3><p>In patients with PH in the PVDOMICS study, female sex was more common, whereas male sex was associated with worse RV function and decreased transplant-free survival, most notably at mild to moderate elevation of PVR.</p></div><div><h3>Trial Registry</h3><p><span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>; No.: <span><span>NCT02980887</span><svg><path></path></svg></span>; URL: <span><span>www.clinicaltrials.gov</span><svg><path></path></svg></span></p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789224000126/pdfft?md5=621a5785c04264fd9403c74859455b8d&pid=1-s2.0-S2949789224000126-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140269592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemodynamic Risk Assessment by Thermodilution and Direct Fick Measurement of Cardiac Output in Pulmonary Hypertension 通过热稀释和直接 Fick 测量肺动脉高压患者的心输出量评估血流动力学风险
Pub Date : 2024-09-01 DOI: 10.1016/j.chpulm.2024.100059

Background

Accurate measurement of cardiac output (CO) is critical in the evaluation and monitoring of pulmonary hypertension (PH). We assessed the accuracy of thermodilution (TD) CO vs direct Fick (DF) CO among patients with PH and evaluated whether the method of CO measurement affected diagnosis or risk assessment.

Research Question

Does using Thermodilution CO as compared to Direct Fick CO alter hemodynamic risk status in PH?

Study Design and Methods

We included patients who had undergone a right heart catheterization with both TD CO and DF CO measurements at University of California, Los Angeles between January 2021 and January 2023. Based on the cardiac index, patients were classified into low-, intermediate-, or high-risk hemodynamic status according to the European Society of Cardiology/European Respiratory Society guidelines.

Results

The analysis included 116 patients with PH. Of the patients, 55% were on PH therapy at the time of catheterization. The median age was 59 years (25th-75th percentile, 50-69), and 63% were female. The median TD CO and DF CO were 4.6 L/min (25th-75th percentile, 3.6-6.0) and 5.3 L/min (25th-75th percentile, 4.2-7.0) (P = .007), respectively. Bland-Altman analysis revealed a mean bias of −0.64 L/min. Median DF pulmonary vascular resistance and TD pulmonary vascular resistance were 4.7 Wood units (25th-75th percentile, 2.7-6.6) and 5.6 Wood units (25th-75th percentile, 3.0-8.0), respectively. Among patients with a low TD cardiac index, almost 40% had a preserved DF cardiac index. There was 78% agreement between DF and TD hemodynamic risk status. Using TD over DF reclassified 8% of patients with precapillary PH (n = 101) from low-risk into intermediate- or high-risk hemodynamic status. TD had a sensitivity of 97% for appropriately risk stratifying patients into intermediate-/high-risk status but a specificity of 73%. Overall, there was a strong correlation between DF CO and TD CO (concordance correlation coefficient, 0.81; 25th-75th percentile, 0.74-0.86).

Interpretation

Hemodynamic risk status was concordant between TD and DF measurements in almost 80% of patients. Oxygen consumption measurement should be considered if available on index right heart catheterization in patients with PH to aid in hemodynamic risk stratification or in whom strict pulmonary vascular resistance calculations are required.

背景准确测量心输出量(CO)对于评估和监测肺动脉高压(PH)至关重要。我们评估了热稀释(TD)CO 与直接菲克(DF)CO 在 PH 患者中的准确性,并评估了 CO 测量方法是否会影响诊断或风险评估。研究设计与方法我们纳入了 2021 年 1 月至 2023 年 1 月期间在加利福尼亚大学洛杉矶分校接受右心导管检查并进行 TD CO 和 DF CO 测量的患者。根据欧洲心脏病学会/欧洲呼吸学会指南,根据心脏指数将患者分为低、中、高风险血流动力学状态。其中 55% 的患者在接受导管检查时正在接受 PH 治疗。中位年龄为59岁(第25-75百分位数,50-69岁),63%为女性。TD CO 和 DF CO 的中位数分别为 4.6 升/分钟(第 25-75 百分位数,3.6-6.0)和 5.3 升/分钟(第 25-75 百分位数,4.2-7.0)(P = .007)。Bland-Altman 分析显示平均偏差为-0.64 升/分钟。中位 DF 肺血管阻力和 TD 肺血管阻力分别为 4.7 伍德单位(第 25-75 百分位数,2.7-6.6)和 5.6 伍德单位(第 25-75 百分位数,3.0-8.0)。在 TD 心脏指数较低的患者中,近 40% 的患者的 DF 心脏指数保持不变。DF 和 TD 血流动力学风险状态的一致性为 78%。在毛细血管前 PH 患者(n = 101)中,使用 TD 而非 DF 可将 8% 的患者从低风险血流动力学状态重新分类为中风险或高风险血流动力学状态。TD 对将患者适当风险分层为中危/高危状态的敏感性为 97%,但特异性为 73%。总体而言,DF CO 和 TD CO 之间有很强的相关性(一致性相关系数,0.81;第 25-75 百分位数,0.74-0.86)。如果 PH 患者的右心导管检查指标可用,则应考虑进行耗氧量测量,以帮助进行血流动力学风险分层,或对肺血管阻力进行严格计算。
{"title":"Hemodynamic Risk Assessment by Thermodilution and Direct Fick Measurement of Cardiac Output in Pulmonary Hypertension","authors":"","doi":"10.1016/j.chpulm.2024.100059","DOIUrl":"10.1016/j.chpulm.2024.100059","url":null,"abstract":"<div><h3>Background</h3><p>Accurate measurement of cardiac output (CO) is critical in the evaluation and monitoring of pulmonary hypertension (PH). We assessed the accuracy of thermodilution (TD) CO vs direct Fick (DF) CO among patients with PH and evaluated whether the method of CO measurement affected diagnosis or risk assessment.</p></div><div><h3>Research Question</h3><p>Does using Thermodilution CO as compared to Direct Fick CO alter hemodynamic risk status in PH?</p></div><div><h3>Study Design and Methods</h3><p>We included patients who had undergone a right heart catheterization with both TD CO and DF CO measurements at University of California, Los Angeles between January 2021 and January 2023. Based on the cardiac index, patients were classified into low-, intermediate-, or high-risk hemodynamic status according to the European Society of Cardiology/European Respiratory Society guidelines.</p></div><div><h3>Results</h3><p>The analysis included 116 patients with PH. Of the patients, 55% were on PH therapy at the time of catheterization. The median age was 59 years (25th-75th percentile, 50-69), and 63% were female. The median TD CO and DF CO were 4.6 L/min (25th-75th percentile, 3.6-6.0) and 5.3 L/min (25th-75th percentile, 4.2-7.0) (<em>P</em> = .007), respectively. Bland-Altman analysis revealed a mean bias of −0.64 L/min. Median DF pulmonary vascular resistance and TD pulmonary vascular resistance were 4.7 Wood units (25th-75th percentile, 2.7-6.6) and 5.6 Wood units (25th-75th percentile, 3.0-8.0), respectively. Among patients with a low TD cardiac index, almost 40% had a preserved DF cardiac index. There was 78% agreement between DF and TD hemodynamic risk status. Using TD over DF reclassified 8% of patients with precapillary PH (n = 101) from low-risk into intermediate- or high-risk hemodynamic status. TD had a sensitivity of 97% for appropriately risk stratifying patients into intermediate-/high-risk status but a specificity of 73%. Overall, there was a strong correlation between DF CO and TD CO (concordance correlation coefficient, 0.81; 25th-75th percentile, 0.74-0.86).</p></div><div><h3>Interpretation</h3><p>Hemodynamic risk status was concordant between TD and DF measurements in almost 80% of patients. Oxygen consumption measurement should be considered if available on index right heart catheterization in patients with PH to aid in hemodynamic risk stratification or in whom strict pulmonary vascular resistance calculations are required.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789224000254/pdfft?md5=7c84115efd909aac43ded18806113adf&pid=1-s2.0-S2949789224000254-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Upper Limit of Normal Rate of Lung Function Decline in Healthy Adults in the Framingham Heart Study 弗雷明汉心脏研究中健康成年人肺功能下降率的正常上限
Pub Date : 2024-09-01 DOI: 10.1016/j.chpulm.2024.100058

Background

Lung function declines over the course of adulthood; however, a consensus on the normal range of decline in an individual’s lung function is lacking.

Research Question

What is the normal range and the upper limit of normal (ULN) decline in lung function in adults without prior tobacco use, occupational dust exposure, or a known diagnosis or symptoms of cardiopulmonary disease?

Study Design and Methods

A retrospective analysis of healthy individuals who have never smoked (N = 1,305) from the Framingham Heart Study with repeated lung function meeting standards for acceptability and reproducibility was conducted. Longitudinal change was derived using a linear mixed effects model and estimated to a 6-year interval. The ULN decline was defined as the 95th percentile.

Results

The mean follow-up between spirometry examinations was 5.5 years, whereas the mean follow-up between diffusing capacity for carbon monoxide studies was 5.9 years. Decline in FEV1, FVC, and D accelerated with age, whereas decline in FEV1/FVC decelerated with age. Decline varied with sex, age, and height. Over a 6-year period, the ULN decline in FEV1 ranged from 383 to 667 mL, and the ULN decline in Dlco ranged from 3.6 to 9.5 mL/min/mm Hg. Overall, male individuals had faster absolute rates of decline than female individuals, whereas relative (%) rates of decline were similar between sexes.

Interpretation

Lung function decline is nonlinear and accelerates with age. In this cohort, the ULN decline over 6 years often exceeded current guidelines for interpreting significant longitudinal change in lung function.

研究背景肺功能在成年后会逐渐下降;然而,人们对个人肺功能下降的正常范围还缺乏共识。研究问题对于没有吸烟史、职业性粉尘暴露或已知心肺疾病诊断或症状的成年人,肺功能下降的正常范围和正常上限(ULN)是多少?研究设计与方法对弗雷明汉心脏研究中从未吸烟的健康人(N = 1,305)进行回顾性分析,重复肺功能符合可接受性和可重复性标准。采用线性混合效应模型得出纵向变化,并以 6 年为间隔进行估算。结果两次肺活量检查之间的平均随访时间为 5.5 年,而两次一氧化碳弥散容量检查之间的平均随访时间为 5.9 年。FEV1、FVC和D的下降速度随年龄增长而加快,而FEV1/FVC的下降速度随年龄增长而减慢。下降速度因性别、年龄和身高而异。在 6 年的时间里,FEV1 下降的超限值从 383 毫升到 667 毫升不等,Dlco 下降的超限值从 3.6 毫升/分钟/毫米汞柱到 9.5 毫升/分钟/毫米汞柱不等。总体而言,男性的绝对下降率比女性快,而男女之间的相对下降率(%)相似。在该队列中,6 年的 ULN 下降率往往超过了目前用于解释肺功能显著纵向变化的指南。
{"title":"The Upper Limit of Normal Rate of Lung Function Decline in Healthy Adults in the Framingham Heart Study","authors":"","doi":"10.1016/j.chpulm.2024.100058","DOIUrl":"10.1016/j.chpulm.2024.100058","url":null,"abstract":"<div><h3>Background</h3><p>Lung function declines over the course of adulthood; however, a consensus on the normal range of decline in an individual’s lung function is lacking.</p></div><div><h3>Research Question</h3><p>What is the normal range and the upper limit of normal (ULN) decline in lung function in adults without prior tobacco use, occupational dust exposure, or a known diagnosis or symptoms of cardiopulmonary disease?</p></div><div><h3>Study Design and Methods</h3><p>A retrospective analysis of healthy individuals who have never smoked (N = 1,305) from the Framingham Heart Study with repeated lung function meeting standards for acceptability and reproducibility was conducted. Longitudinal change was derived using a linear mixed effects model and estimated to a 6-year interval. The ULN decline was defined as the 95th percentile.</p></div><div><h3>Results</h3><p>The mean follow-up between spirometry examinations was 5.5 years, whereas the mean follow-up between diffusing capacity for carbon monoxide studies was 5.9 years. Decline in FEV<sub>1</sub>, FVC, and D accelerated with age, whereas decline in FEV<sub>1</sub>/FVC decelerated with age. Decline varied with sex, age, and height. Over a 6-year period, the ULN decline in FEV<sub>1</sub> ranged from 383 to 667 mL, and the ULN decline in D<span>lco</span> ranged from 3.6 to 9.5 mL/min/mm Hg. Overall, male individuals had faster absolute rates of decline than female individuals, whereas relative (%) rates of decline were similar between sexes.</p></div><div><h3>Interpretation</h3><p>Lung function decline is nonlinear and accelerates with age. In this cohort, the ULN decline over 6 years often exceeded current guidelines for interpreting significant longitudinal change in lung function.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789224000242/pdfft?md5=56df745686b5a15555aef18bf84cad8f&pid=1-s2.0-S2949789224000242-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140794374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Annual Adherence of Asian American Individuals in a Lung Cancer Screening Program Compared With Other Racial Groups 与其他种族群体相比,参加肺癌筛查项目的亚裔美国人每年的坚持率较低
Pub Date : 2024-09-01 DOI: 10.1016/j.chpulm.2024.100051

Background

Racial differences in lung cancer screening (LCS) eligibility and outcomes persist despite recent expansion of the US Preventive Services Task Force criteria and greater recognition of screening disparities.

Research Question

What is the annual screening adherence rate for US Preventive Services Task Force-eligible Asian American individuals receiving LCS through a centralized screening program?

Study Design and Methods

Individuals screened through a centralized LCS program were identified retrospectively using the Jefferson LCS Program Registry. Sociodemographic and clinical data were extracted from the prospectively maintained registry. Frequency statistics were compared by race including among Asian American subgroups, and multivariate logistic regression was carried out for annual adherence with LCS.

Results

Among 2,257 individuals in the study cohort, 122 participants (5.4%) self-identified their race as Asian American. Compared with other racial groups, Asian American individuals had significant differences in sex distribution, educational attainment, and insurance status. The most common Asian American race subgroups were Chinese American, Korean American, and Vietnamese American, and significant differences in cigarette smoking intensity were seen between these groups. Among currently smoking individuals, Asian American individuals reported interest in tobacco counseling and pharmacotherapy treatment at rates similar to those of other races. Asian American individuals had significantly lower odds of adherence (adjusted OR, 0.42; 95% CI, 0.26-0.69) with annual screening than other races, even after adjustment for age, sex, educational attainment, smoking status, and COPD.

Interpretation

Asian American individuals in our centralized LCS program have increased rates of lung cancer-related factors including low educational attainment, high smoking prevalence, low tobacco cessation, and low annual LCS adherence compared with other racial groups. This gap highlights the need for greater focus on culturally tailored early detection strategies for this underserved population.

研究背景尽管美国预防服务工作组最近扩大了肺癌筛查(LCS)的标准,而且对筛查差异的认识也有所提高,但肺癌筛查(LCS)资格和结果的种族差异仍然存在。研究问题通过集中筛查计划接受 LCS 的符合美国预防服务工作组标准的亚裔美国人的年度筛查坚持率是多少?社会人口学和临床数据均从前瞻性维护的登记表中提取。结果在研究队列中的 2,257 人中,有 122 人(5.4%)自称其种族为亚裔美国人。与其他种族群体相比,亚裔美国人在性别分布、教育程度和保险状况方面存在显著差异。最常见的亚裔美国人种族亚群是华裔美国人、韩裔美国人和越南裔美国人,这些亚群之间的吸烟强度存在显著差异。在目前吸烟的人群中,亚裔美国人对烟草咨询和药物治疗感兴趣的比例与其他种族相似。即使对年龄、性别、教育程度、吸烟状况和慢性阻塞性肺病进行调整后,亚裔美国人坚持年度筛查的几率(调整后OR,0.42;95% CI,0.26-0.69)仍明显低于其他种族。这一差距凸显了我们需要更加关注针对这一服务不足人群的文化定制早期检测策略。
{"title":"Annual Adherence of Asian American Individuals in a Lung Cancer Screening Program Compared With Other Racial Groups","authors":"","doi":"10.1016/j.chpulm.2024.100051","DOIUrl":"10.1016/j.chpulm.2024.100051","url":null,"abstract":"<div><h3>Background</h3><p>Racial differences in lung cancer screening (LCS) eligibility and outcomes persist despite recent expansion of the US Preventive Services Task Force criteria and greater recognition of screening disparities.</p></div><div><h3>Research Question</h3><p>What is the annual screening adherence rate for US Preventive Services Task Force-eligible Asian American individuals receiving LCS through a centralized screening program?</p></div><div><h3>Study Design and Methods</h3><p>Individuals screened through a centralized LCS program were identified retrospectively using the Jefferson LCS Program Registry. Sociodemographic and clinical data were extracted from the prospectively maintained registry. Frequency statistics were compared by race including among Asian American subgroups, and multivariate logistic regression was carried out for annual adherence with LCS.</p></div><div><h3>Results</h3><p>Among 2,257 individuals in the study cohort, 122 participants (5.4%) self-identified their race as Asian American. Compared with other racial groups, Asian American individuals had significant differences in sex distribution, educational attainment, and insurance status. The most common Asian American race subgroups were Chinese American, Korean American, and Vietnamese American, and significant differences in cigarette smoking intensity were seen between these groups. Among currently smoking individuals, Asian American individuals reported interest in tobacco counseling and pharmacotherapy treatment at rates similar to those of other races. Asian American individuals had significantly lower odds of adherence (adjusted OR, 0.42; 95% CI, 0.26-0.69) with annual screening than other races, even after adjustment for age, sex, educational attainment, smoking status, and COPD.</p></div><div><h3>Interpretation</h3><p>Asian American individuals in our centralized LCS program have increased rates of lung cancer-related factors including low educational attainment, high smoking prevalence, low tobacco cessation, and low annual LCS adherence compared with other racial groups. This gap highlights the need for greater focus on culturally tailored early detection strategies for this underserved population.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789224000175/pdfft?md5=916692871b03fbf85f4c203e3deb0e29&pid=1-s2.0-S2949789224000175-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140400628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strategies for the Management of a Pulmonary Function Laboratory 肺功能实验室的管理策略
Pub Date : 2024-09-01 DOI: 10.1016/j.chpulm.2024.100055

Pulmonary function tests (PFTs) are imperative to the diagnosis of people with respiratory symptoms and lung disease and to disease management. PFTs require expertise to obtain both high-quality tests and proficiency in test interpretation. In this review, we provide recommendations for obtaining high-quality test results in an efficient and cost-effective manner guided by available evidence and expert opinion. The medical director plays a critical role in pulmonary laboratory operations and ultimately is responsible for laboratory performance. Responsibilities of the medical director are reviewed and discussed. Quality control is an underappreciated part of the pulmonary laboratory that is that is necessary high-quality tests. What constitutes a complete PFT and the order that tests are performed may differ among laboratories. We suggest an approach to the performance of spirometry, bronchodilator-responsiveness testing, diffusing capacity, lung volumes, and tests of respiratory muscle strength that maximizes clinical usefulness and laboratory efficiency. Appropriate resources, time, and expertise are needed to run an efficient pulmonary function laboratory capable of performing high-quality testing.

肺功能检查(PFT)是诊断呼吸道症状和肺部疾病患者以及进行疾病管理的必要手段。肺功能检查需要专业人员才能获得高质量的测试结果和熟练的测试解读能力。在本综述中,我们以现有证据和专家意见为指导,就如何以高效、经济的方式获得高质量的测试结果提出了建议。医务主任在肺实验室的运作中起着至关重要的作用,并最终对实验室的绩效负责。本文对医务主任的职责进行了回顾和讨论。质量控制是肺病实验室中一个未得到充分重视的部分,它是高质量检测所必需的。什么是完整的 PFT 以及进行测试的顺序可能因实验室而异。我们建议采用一种方法来进行肺活量测定、支气管扩张剂反应性测试、弥散容量、肺容积和呼吸肌强度测试,以最大限度地提高临床实用性和实验室效率。要运行一个能进行高质量测试的高效肺功能实验室,需要适当的资源、时间和专业知识。
{"title":"Strategies for the Management of a Pulmonary Function Laboratory","authors":"","doi":"10.1016/j.chpulm.2024.100055","DOIUrl":"10.1016/j.chpulm.2024.100055","url":null,"abstract":"<div><p>Pulmonary function tests (PFTs) are imperative to the diagnosis of people with respiratory symptoms and lung disease and to disease management. PFTs require expertise to obtain both high-quality tests and proficiency in test interpretation. In this review, we provide recommendations for obtaining high-quality test results in an efficient and cost-effective manner guided by available evidence and expert opinion. The medical director plays a critical role in pulmonary laboratory operations and ultimately is responsible for laboratory performance. Responsibilities of the medical director are reviewed and discussed. Quality control is an underappreciated part of the pulmonary laboratory that is that is necessary high-quality tests. What constitutes a complete PFT and the order that tests are performed may differ among laboratories. We suggest an approach to the performance of spirometry, bronchodilator-responsiveness testing, diffusing capacity, lung volumes, and tests of respiratory muscle strength that maximizes clinical usefulness and laboratory efficiency. Appropriate resources, time, and expertise are needed to run an efficient pulmonary function laboratory capable of performing high-quality testing.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789224000217/pdfft?md5=4f7005f26a875152a5911e191747e632&pid=1-s2.0-S2949789224000217-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140763880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COUNTERPOINT: Liquid Markers for Risk Stratification of Pulmonary Nodules, Ready for Prime Time? Not Yet! 用于肺结节风险分层的液体标记物,准备好了吗?还没
Pub Date : 2024-09-01 DOI: 10.1016/j.chpulm.2024.100070
{"title":"COUNTERPOINT: Liquid Markers for Risk Stratification of Pulmonary Nodules, Ready for Prime Time? Not Yet!","authors":"","doi":"10.1016/j.chpulm.2024.100070","DOIUrl":"10.1016/j.chpulm.2024.100070","url":null,"abstract":"","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789224000369/pdfft?md5=f9b4708ae7e114b87decd25609fd33b7&pid=1-s2.0-S2949789224000369-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141390519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Qualitative Study Identifying the Potential Risk Mechanisms Leading to Hospitalization for Patients With Chronic Lung Disease 一项定性研究,确定导致慢性肺病患者住院的潜在风险机制
Pub Date : 2024-09-01 DOI: 10.1016/j.chpulm.2024.100060

Background

Care management programs for chronic lung disease attempt to reduce hospitalizations, yet have not reliably achieved this goal. A key limitation of many programs is that they target patients with characteristics associated with hospitalization risk, but do not specifically modify the mechanisms that lead to hospitalization.

Research Question

What are the common mechanisms underlying known patient-level risk characteristics leading to hospitalizations for acute exacerbations of chronic lung disease?

Study Design and Methods

We conducted a qualitative study of patients admitted to the University of Pennsylvania Health System with acute exacerbations of chronic lung disease between January and September 2019. We interviewed patients, their family caregivers, and their inpatient and outpatient clinicians about experiences leading up to the hospitalization. We analyzed the interview transcripts using triangulation and abductive analytic methods.

Results

We conducted 69 interviews focused on the admission of 22 patients with a median age of 66 years (interquartile range, 60-70 years), of whom 16 patients (73%) were female and 14 patients (64%) were Black. We interviewed 22 patients, 14 caregivers, 19 inpatient clinicians, and 14 outpatient clinicians. We triangulated the available interview data for each patient admission and identified the underlying mechanisms of how several known patient characteristics associated with risk actually led to hospitalization. These mechanisms included limited capacity for home management of acute symptom changes, barriers to accessing care, chronic functional limitations, and comorbid behavioral health disorders. Importantly, many of the clinical, social, and behavioral mechanisms underlying hospitalizations were present for months or years before the symptoms that prompted inpatient care.

Interpretation

Care management programs should be built to target specific clinical, social, and behavioral mechanisms that directly lead to hospitalization. Upstream interventions that reduce hospitalization risk are possible given that many contributory mechanisms are present for months or years before the onset of acute exacerbations.

研究背景慢性肺病的护理管理计划试图减少住院率,但并未可靠地实现这一目标。研究问题已知的导致慢性肺病急性加重住院的患者水平风险特征的共同机制是什么?研究设计和方法我们对2019年1月至9月期间宾夕法尼亚大学卫生系统收治的慢性肺病急性加重患者进行了一项定性研究。我们就住院前的经历采访了患者、其家庭护理人员以及住院和门诊临床医生。我们采用三角测量法和归纳分析法对访谈记录进行了分析。结果我们进行了 69 次访谈,重点关注 22 名患者的入院情况,他们的中位年龄为 66 岁(四分位间范围为 60-70 岁),其中 16 名患者(73%)为女性,14 名患者(64%)为黑人。我们对 22 名患者、14 名护理人员、19 名住院临床医生和 14 名门诊临床医生进行了访谈。我们对每位入院患者的现有访谈数据进行了三角测量,并确定了与风险相关的几个已知患者特征是如何导致住院治疗的潜在机制。这些机制包括在家处理急性症状变化的能力有限、获得护理的障碍、慢性功能限制以及合并行为健康疾病。重要的是,许多导致住院治疗的临床、社会和行为机制在症状出现前数月或数年就已存在。鉴于许多致病机制在急性加重发作前数月或数年就已存在,因此可以采取上游干预措施来降低住院风险。
{"title":"A Qualitative Study Identifying the Potential Risk Mechanisms Leading to Hospitalization for Patients With Chronic Lung Disease","authors":"","doi":"10.1016/j.chpulm.2024.100060","DOIUrl":"10.1016/j.chpulm.2024.100060","url":null,"abstract":"<div><h3>Background</h3><p>Care management programs for chronic lung disease attempt to reduce hospitalizations, yet have not reliably achieved this goal. A key limitation of many programs is that they target patients with characteristics associated with hospitalization risk, but do not specifically modify the mechanisms that lead to hospitalization.</p></div><div><h3>Research Question</h3><p>What are the common mechanisms underlying known patient-level risk characteristics leading to hospitalizations for acute exacerbations of chronic lung disease?</p></div><div><h3>Study Design and Methods</h3><p>We conducted a qualitative study of patients admitted to the University of Pennsylvania Health System with acute exacerbations of chronic lung disease between January and September 2019. We interviewed patients, their family caregivers, and their inpatient and outpatient clinicians about experiences leading up to the hospitalization. We analyzed the interview transcripts using triangulation and abductive analytic methods.</p></div><div><h3>Results</h3><p>We conducted 69 interviews focused on the admission of 22 patients with a median age of 66 years (interquartile range, 60-70 years), of whom 16 patients (73%) were female and 14 patients (64%) were Black. We interviewed 22 patients, 14 caregivers, 19 inpatient clinicians, and 14 outpatient clinicians. We triangulated the available interview data for each patient admission and identified the underlying mechanisms of how several known patient characteristics associated with risk actually led to hospitalization. These mechanisms included limited capacity for home management of acute symptom changes, barriers to accessing care, chronic functional limitations, and comorbid behavioral health disorders. Importantly, many of the clinical, social, and behavioral mechanisms underlying hospitalizations were present for months or years before the symptoms that prompted inpatient care.</p></div><div><h3>Interpretation</h3><p>Care management programs should be built to target specific clinical, social, and behavioral mechanisms that directly lead to hospitalization. Upstream interventions that reduce hospitalization risk are possible given that many contributory mechanisms are present for months or years before the onset of acute exacerbations.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789224000266/pdfft?md5=9aaaa951c79ee63460936c5365e555be&pid=1-s2.0-S2949789224000266-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141026018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
CHEST pulmonary
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1